Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-013680
Filing Date
2025-05-19
Accepted
2025-05-19 17:46:06
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 14319
2 JOINT FILING AGREEMENT ex-99-05192025_090507.htm EX-99.1 4560
  Complete submission text file 0001415889-25-013680.txt   20732
Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472 857-204-4583
iTeos Therapeutics, Inc. (Subject) CIK: 0001808865 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91596 | Film No.: 25965299
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)